New gram negative antibiotics

Here are some new gram-negative antibiotics that have been approved or are in development:

  1. Ceftobiprole (Dificid): Approved in 2014, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii.
  2. Ceftolozane-tazobactam (Zerbaxa): Approved in 2014, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae.
  3. Meropenem-vaborbactam (Vabomere): Approved in 2017, this carbapenem antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii.
  4. Plazomicin (Zemaira): Approved in 2017, this aminoglycoside antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae.
  5. Ceftazidime-avibactam (Avycaz): Approved in 2017, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae.
  6. Lefamulin (Xenleta): Approved in 2019, this pleuromutilin antibiotic is effective against a wide range of gram-negative bacteria, including Streptococcus pneumoniae and Haemophilus influenzae.
  7. Ceftolozane-tazobactam (Teflaro): Approved in 2020, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae.
  8. Ceftobiprole (Fetroja): Approved in 2020, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii.
  9. Ceftazidime-avibactam (Avycaz): Approved in 2020, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae.
  10. Ceftolozane-tazobactam (Zerbaxa): Approved in 2020, this cephalosporin antibiotic is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae.

Some new gram-negative antibiotics in development include:

  1. Ceftobiprole (Fetroja): A cephalosporin antibiotic being developed by Pfizer to treat a range of gram-negative infections, including those caused by Pseudomonas aeruginosa and Acinetobacter baumannii.
  2. Ceftolozane-tazobactam (Zerbaxa): A cephalosporin antibiotic being developed by Merck & Co. to treat a range of gram-negative infections, including those caused by Pseudomonas aeruginosa and Klebsiella pneumoniae.
  3. Lefamulin (Xenleta): A pleuromutilin antibiotic being developed by Nabriva Therapeutics to treat a range of gram-negative infections, including those caused by Streptococcus pneumoniae and Haemophilus influenzae.
  4. Ceftazidime-avibactam (Avycaz): A cephalosporin antibiotic being developed by Allergan to treat a range of gram-negative infections, including those caused by Pseudomonas aeruginosa and Klebsiella pneumoniae.
  5. Ceftolozane-tazobactam (Teflaro): A cephalosporin antibiotic being developed by Forest Laboratories to treat a range of gram-negative infections, including those caused by Pseudomonas aeruginosa and Klebsiella pneumoniae.

Please note that the development and approval of new antibiotics is a complex process, and the availability of these antibiotics may vary depending on the country and region.